Full-Time

Scientist – Applications Sample Preparation

Glyphic Biotechnologies

Glyphic Biotechnologies

11-50 employees

Next-generation protein sequencing platform provider

Compensation Overview

$90.2k - $129.5k/yr

Berkeley, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Requirements
  • Degree in biochemistry, chemical biology, molecular biology, or an equivalent field.
  • Research experience including PhD / MS / BS with 0+ / 2+ / 4+ years of relevant experience.
  • Hands-on experience executing sample preparation protocols across proteomic and nucleic acid-based platforms, generating quantitative readouts across diverse analytical platforms (e.g., LC-MS for proteomics; Illumina, ONT, PacBio, or similar for NGS).
  • Demonstrated skill preparing and processing diverse biological sample types (cell lines, tissue, blood, or other research/clinical matrices) for downstream proteomic and/or genomic analysis.
  • Proficiency with NGS library preparation methods (DNA-seq, RNA-seq, and/or ribosome profiling), including nucleic acid extraction, quantification, amplification, and QC.
  • A track record of applying sample preparation or enrichment methods suited for low-abundance targets or limited input material, including cfDNA and other biofluid-derived analytes.
  • Working knowledge of germline versus somatic sequence variation and its relevance to sample prep and analysis decisions.
  • Understanding of peptide chemistry and strategies to prevent degradation of post-translational modifications (PTMs), such as methylation and phosphorylation.
  • Strong problem-solving skills and close attention to detail.
  • Clear written and verbal communication skills, with the ability to collaborate effectively across diverse scientific and technical backgrounds.
  • Ability to thrive in a fast-paced environment with evolving priorities.
Desired Qualifications
  • Experience with chemical labeling or modification chemistries (e.g., side-chain labeling, ABPP, or similar chemoproteomic approaches) as applied within established sample preparation workflows.
  • Deep familiarity with highly multiplexed, high-sensitivity protein quantification platforms (e.g., nELISA, NuLISA, immunoassays, PLA, or PEA).
  • Experience with nanopore platforms for sequencing or label-free detection.
  • Experience with single-cell or spatial proteomics and transcriptomics.
  • Familiarity with neoantigen discovery workflows that integrate genomic, transcriptomic, and proteomic evidence.
  • Comfort working in R or Python to input experimental results into and navigate established data analysis workflows.
Glyphic Biotechnologies

Glyphic Biotechnologies

View

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.

Company Size

11-50

Company Stage

Early VC

Total Funding

$43M

Headquarters

New York City, New York

Founded

2021

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Glyphic raised $38 million by September 2025, extending runway for platform development.
  • Glyphic posted multiple 2026 hires in Berkeley, signaling active buildout and execution.
  • NIH and Bakar Labs visibility plus 2025 patent publications validate technical momentum.

What critics are saying

  • Glyphic still sells no commercial platform, so revenue depends on unproven hardware delivery in 2026.
  • Protein sequencing must beat mass spectrometry, or customers ignore Glyphic’s expensive workflow.
  • If ProSE misses accuracy or throughput targets, the 2025 Series A becomes a financing trap.

What makes Glyphic Biotechnologies unique

  • Glyphic’s ProSE sequences proteins de novo, one molecule at a time, without databases.
  • Glyphic claims single-molecule discrimination of all 20 amino acids and PTMs in Berkeley, 2026.
  • Glyphic holds issued patents and a 2025 nanopore peptide-sequencing filing around core chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Paid Maternity and Paternity Leave

Home Office Stipend

Wellness Program

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

0%

2 year growth

3%
Labs of Latvia
Dec 3rd, 2024
Latvian LongeVC invests in US startup Glyphic Biotechnologies

Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequencing platform that uses single-molecule technology to analyze the sequence of each protein in a complex protein mixture.

BioPharmaTrend
Nov 25th, 2024
LongeVC Invests in Glyphic Biotechnologies

LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology. This innovation surpasses mass spectrometry by enabling precise sequencing of individual proteins in complex mixtures, enhancing protein analysis and broadening applications in drug discovery and diagnostics. The proteomics market, valued at over $30 billion, is set for growth with such advancements. This aligns with LongeVC's mission to support transformative healthcare technologies.

U.S. Securities and Exchange Commission
Feb 21st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Johnson & Johnson Innovation
Apr 5th, 2023
Awardees of the BLUE KNIGHT™ Resident QuickFire Challenge Strive Toward Inflection Points | Johnson & Johnson Innovation

By: Rachel Rath, Director, BARDA Alliance, Johnson & Johnson Innovation – JLABS & Ashim Subedee, Director, DRIVe Catalyst Office, BARDA

Bakar Labs
Jan 31st, 2023
Glyphic Biotechnologies Wins $409K SBIR Grant From NIH - Bakar Labs

Congratulations to Glyphic Biotechnologies! NIH recently reported the company had been awarded a $409 SBIR grant for their project "Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids." The company is developing and commercializing technology to sequence proteins — instead of DNA. They're hiring!